These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

652 related articles for article (PubMed ID: 30046032)

  • 1. Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound.
    Lipsman N; Meng Y; Bethune AJ; Huang Y; Lam B; Masellis M; Herrmann N; Heyn C; Aubert I; Boutet A; Smith GS; Hynynen K; Black SE
    Nat Commun; 2018 Jul; 9(1):2336. PubMed ID: 30046032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Focused ultrasound-mediated blood-brain barrier opening in Alzheimer's disease: long-term safety, imaging, and cognitive outcomes.
    Rezai AR; Ranjan M; Haut MW; Carpenter J; D'Haese PF; Mehta RI; Najib U; Wang P; Claassen DO; Chazen JL; Krishna V; Deib G; Zibly Z; Hodder SL; Wilhelmsen KC; Finomore V; Konrad PE; Kaplitt M;
    J Neurosurg; 2023 Jul; 139(1):275-283. PubMed ID: 36334289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcranial blood-brain barrier opening in Alzheimer's disease patients using a portable focused ultrasound system with real-time 2-D cavitation mapping.
    Bae S; Liu K; Pouliopoulos AN; Ji R; Jiménez-Gambín S; Yousefian O; Kline-Schoder AR; Batts AJ; Tsitsos FN; Kokossis D; Mintz A; Honig LS; Konofagou EE
    Theranostics; 2024; 14(11):4519-4535. PubMed ID: 39113808
    [No Abstract]   [Full Text] [Related]  

  • 4. Blood-brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound.
    Meng Y; Goubran M; Rabin JS; McSweeney M; Ottoy J; Pople CB; Huang Y; Storace A; Ozzoude M; Bethune A; Lam B; Swardfager W; Heyn C; Abrahao A; Davidson B; Hamani C; Aubert I; Zetterberg H; Ashton NJ; Karikari TK; Blennow K; Black SE; Hynynen K; Lipsman N
    Brain; 2023 Mar; 146(3):865-872. PubMed ID: 36694943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of amyloid PET/CT with
    Ferrari C; Caputo P; Pisani AR; Nappi AG; Branca A; Lavelli V; Rubini G
    Hell J Nucl Med; 2019; 22 Suppl 2():142-152. PubMed ID: 31802055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive hippocampal blood-brain barrier opening in Alzheimer's disease with focused ultrasound.
    Rezai AR; Ranjan M; D'Haese PF; Haut MW; Carpenter J; Najib U; Mehta RI; Chazen JL; Zibly Z; Yates JR; Hodder SL; Kaplitt M
    Proc Natl Acad Sci U S A; 2020 Apr; 117(17):9180-9182. PubMed ID: 32284421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer's disease and healthy controls.
    Barthel H; Luthardt J; Becker G; Patt M; Hammerstein E; Hartwig K; Eggers B; Sattler B; Schildan A; Hesse S; Meyer PM; Wolf H; Zimmermann T; Reischl J; Rohde B; Gertz HJ; Reininger C; Sabri O
    Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1702-14. PubMed ID: 21547601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood-brain barrier opening with focused ultrasound in Parkinson's disease dementia.
    Gasca-Salas C; Fernández-Rodríguez B; Pineda-Pardo JA; Rodríguez-Rojas R; Obeso I; Hernández-Fernández F; Del Álamo M; Mata D; Guida P; Ordás-Bandera C; Montero-Roblas JI; Martínez-Fernández R; Foffani G; Rachmilevitch I; Obeso JA
    Nat Commun; 2021 Feb; 12(1):779. PubMed ID: 33536430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease with an implantable ultrasound device.
    Epelbaum S; Burgos N; Canney M; Matthews D; Houot M; Santin MD; Desseaux C; Bouchoux G; Stroer S; Martin C; Habert MO; Levy M; Bah A; Martin K; Delatour B; Riche M; Dubois B; Belin L; Carpentier A
    Alzheimers Res Ther; 2022 Mar; 14(1):40. PubMed ID: 35260178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [
    Stenzel J; Rühlmann C; Lindner T; Polei S; Teipel S; Kurth J; Rominger A; Krause BJ; Vollmar B; Kuhla A
    Curr Alzheimer Res; 2019; 16(1):49-55. PubMed ID: 30345916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Scanning ultrasound in the absence of blood-brain barrier opening is not sufficient to clear β-amyloid plaques in the APP23 mouse model of Alzheimer's disease.
    Leinenga G; Koh WK; Götz J
    Brain Res Bull; 2019 Nov; 153():8-14. PubMed ID: 31400496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations of quantitative susceptibility mapping with Alzheimer's disease clinical and imaging markers.
    Cogswell PM; Wiste HJ; Senjem ML; Gunter JL; Weigand SD; Schwarz CG; Arani A; Therneau TM; Lowe VJ; Knopman DS; Botha H; Graff-Radford J; Jones DT; Kantarci K; Vemuri P; Boeve BF; Mielke MM; Petersen RC; Jack CR
    Neuroimage; 2021 Jan; 224():117433. PubMed ID: 33035667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of partial volume effect correction on cerebral β-amyloid imaging in APP-Swe mice using [(18)F]-florbetaben PET.
    Brendel M; Delker A; Rötzer C; Böning G; Carlsen J; Cyran C; Mille E; Gildehaus FJ; Cumming P; Baumann K; Steiner H; Haass C; Herms J; Bartenstein P; Rominger A
    Neuroimage; 2014 Jan; 84():843-53. PubMed ID: 24055703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extensive frontal focused ultrasound mediated blood-brain barrier opening for the treatment of Alzheimer's disease: a proof-of-concept study.
    Park SH; Baik K; Jeon S; Chang WS; Ye BS; Chang JW
    Transl Neurodegener; 2021 Nov; 10(1):44. PubMed ID: 34740367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
    Mattsson N; Insel PS; Donohue M; Landau S; Jagust WJ; Shaw LM; Trojanowski JQ; Zetterberg H; Blennow K; Weiner MW;
    Brain; 2015 Mar; 138(Pt 3):772-83. PubMed ID: 25541191
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease.
    Rezai AR; D'Haese PF; Finomore V; Carpenter J; Ranjan M; Wilhelmsen K; Mehta RI; Wang P; Najib U; Vieira Ligo Teixeira C; Arsiwala T; Tarabishy A; Tirumalai P; Claassen DO; Hodder S; Haut MW
    N Engl J Med; 2024 Jan; 390(1):55-62. PubMed ID: 38169490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.
    Sabri O; Sabbagh MN; Seibyl J; Barthel H; Akatsu H; Ouchi Y; Senda K; Murayama S; Ishii K; Takao M; Beach TG; Rowe CC; Leverenz JB; Ghetti B; Ironside JW; Catafau AM; Stephens AW; Mueller A; Koglin N; Hoffmann A; Roth K; Reininger C; Schulz-Schaeffer WJ;
    Alzheimers Dement; 2015 Aug; 11(8):964-74. PubMed ID: 25824567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease.
    Ossenkoppele R; Schonhaut DR; Schöll M; Lockhart SN; Ayakta N; Baker SL; O'Neil JP; Janabi M; Lazaris A; Cantwell A; Vogel J; Santos M; Miller ZA; Bettcher BM; Vossel KA; Kramer JH; Gorno-Tempini ML; Miller BL; Jagust WJ; Rabinovici GD
    Brain; 2016 May; 139(Pt 5):1551-67. PubMed ID: 26962052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focused ultrasound therapy for Alzheimer's disease: exploring the potential for targeted amyloid disaggregation.
    Scott K; Klaus SP
    Front Neurol; 2024; 15():1426075. PubMed ID: 39165269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.